Hoffmann-La Roche: Neoplasm Metastasis trials
The registry lists 24 Neoplasm Metastasis studies with Hoffmann-La Roche as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 7Phase 2 7Phase 3 7Phase 4 3No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingNCT04449874Phase 1
- Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI TherapyCompletedNCT03333655Phase 4
- Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic TumorsCompletedNCT02794571Phase 1
- A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast CancerCompletedNCT02716792Phase 3
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingNCT02650401Phase 1/2
- Outcomes of FoundationOne Directed Therapy in Cancer of Unknown PrimaryCompletedNCT02628379
- A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone DiseaseCompletedNCT02564107Phase 4
- A Study of Ibandronate (Bondronat) in Participants With Malignant Bone DiseaseCompletedNCT02561039Phase 3
- A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast CancerCompletedNCT02553707Phase 4
- Study of Intravenous RXDX-107 in Patients With Solid TumorsTerminatedNCT02548390Phase 1
- FoundationOne™ Test Registry StudyCompletedNCT01851213
- A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2
- A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.CompletedNCT00502736Phase 2
- A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.WithdrawnNCT00478270Phase 2
- A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast CancerCompletedNCT00109239Phase 3
- A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal CancerCompletedNCT00109070Phase 3
- A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone DiseaseTerminatedNCT00099203Phase 3
- A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe PainTerminatedNCT00099177Phase 3
- A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a TaxaneCompletedNCT00097487
- A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer StudyCompletedNCT00096967Phase 3
- A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell CarcinomaCompletedNCT00081614Phase 2
- Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone MetastasesCompletedNCT00060138Phase 1/2
- An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast CancerCompletedNCT00051779Phase 1